Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study

Eur J Pediatr. 2021 May;180(5):1467-1475. doi: 10.1007/s00431-020-03888-x. Epub 2021 Jan 6.

Abstract

A new pediatric fixed combination of beclometasone dipropionate (BDP) 50 μg and formoterol fumarate (FF) 6 μg via pressurized metered-dose inhaler (pMDI) (CHF1535, Chiesi, Italy) was investigated. In a double-blind, randomized, placebo-controlled, cross-over study, a single CHF1535 administration using AeroChamber Plus™ spacer device (2 actuations, total dose BDP 100 μg/FF 12 μg) was compared to the same pMDI free combination in 56 asthmatic children aged ≥ 5 and < 12 years. Primary efficacy variable was forced expiratory volume during the first second (FEV1) area under the curve corrected by time over 12 h following morning dose (AUC0-12h). Further CHF1535 doses (50 μg/6 μg, 100 μg/12 μg, and 200 μg/24 μg) were also explored. Adverse events, electrocardiogram, and vital signs were monitored for safety. CHF1535 was non-inferior to free combination [adjusted mean difference (95% CI) 0.004 L (- 0.050, 0.041] with lower confidence limit greater than the limit set at 0.1 L. FEV1 AUC0-12h of each CHF1535 dose vs placebo were 0.037 L (p = 0.160), 0.119 L (p < 0.001), and 0.094 (p < 0.001) for 50/6, 100/12, and 200/24, respectively. No safety signals were found.Conclusion: CHF1535 was as effective as free combination BDP/FF, with a trend towards a dose-related response. All treatments were safe.Trial registration: ClinicalTrials.gov ID: NCT01584492 What is Known: •Inhaled pressurized metered-dose solutions (pMDI) are the preferred treatment for pediatric asthma. •Combination therapy of inhaled corticosteroids and long-acting β2- agonists is a well-established approach to control airway inflammation and airway obstruction also in pediatric patients. What is New: •A novel pediatric pMDI fixed combination of beclomethasone dipropionate 50 μg and formoterol fumarate 6 μg (CHF 1535) was non-inferior to the free combination at the same dose in pulmonary function over the 12-h post-dose period in asthmatic children, with trend towards a dose-related response.

Keywords: Beclometasone; Fixed combination; Formoterol; Pediatric asthma; Pressurized metered-dose inhaler.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Anti-Asthmatic Agents* / pharmacology
  • Asthma* / drug therapy
  • Beclomethasone / pharmacology
  • Beclomethasone / therapeutic use
  • Bronchodilator Agents / therapeutic use
  • Child
  • Cross-Over Studies
  • Double-Blind Method
  • Drug Combinations
  • Forced Expiratory Volume
  • Formoterol Fumarate / pharmacology
  • Formoterol Fumarate / therapeutic use
  • Humans
  • Italy
  • Metered Dose Inhalers
  • Nebulizers and Vaporizers
  • Treatment Outcome

Substances

  • Anti-Asthmatic Agents
  • Bronchodilator Agents
  • Drug Combinations
  • Beclomethasone
  • Formoterol Fumarate

Associated data

  • ClinicalTrials.gov/NCT01584492